IDEAYA Biosciences, Inc. IDYA R2KR3KPHARMA
Company Overview
IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Recent Developments
- Dec 2025 Revenue of $218.71M (+3024.4% YoY); net profit $-113.70M.
- Trailing 12 Months Year-on-year growth — revenue +3024.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 3,024.43% |
Stock Price Performance
| 1 Year: | +63.23% |
| 6 Months: | +20.10% |
| 3 Months: | +40.90% |
| 1 Month: | +9.99% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)57.75 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | IDYA IDEAYA Biosciences, Inc. R2KR3KPHARMA | 39.86 | -20.76 | $3.84B | 0.00% | -15.17% | -16.22% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 8.97M | 7.25M | 8.76M | 8.98M | 11.36M | 5.85M | 29.70M | 7.88M | 3.54M | 8.04M | 0 | 0 | 0 | - | - | 207.83M | - | 6.56M | 8.86M |
| Operating Income | - | -7.57M | -13.63M | - | -10.09M | -11.23M | -11.62M | - | -12.48M | -12.59M | -5.00M | -9.13M | -11.05M | -11.71M | -14.22M | -22.50M | 660.00K | -26.28M | -32.71M | -33.53M | -51.02M | -64.93M | -66.89M | -84.39M | -88.81M | 108.45M | - | -108.54M | -122.29M |
| Net Income | -5.74M | -7.00M | -13.05M | -8.56M | -9.57M | -10.66M | -10.97M | -10.78M | -12.04M | -12.39M | -4.93M | -9.02M | -10.95M | -11.58M | -14.01M | -22.06M | 1.61M | -23.64M | -27.93M | -27.44M | -39.57M | -52.77M | -51.82M | -72.18M | -77.49M | 119.24M | - | -98.54M | -112.45M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | -0.33 | -0.31 | -0.36 | -0.57 | 0.04 | -0.49 | -0.50 | -0.46 | -0.53 | -0.68 | -0.60 | -0.82 | -0.88 | 1.33 | - | -1.11 | -1.22 |
| R&D Expense | - | 6.43M | 12.54M | - | 8.00M | 8.86M | 8.92M | - | 9.03M | 8.60M | 10.03M | 11.57M | 14.98M | 15.50M | 19.66M | 22.80M | 22.37M | 27.86M | 29.18M | 33.70M | 42.80M | 54.53M | 57.15M | 70.89M | 74.23M | 82.99M | 86.60M | 95.73M | 108.69M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 19.54M | - | 50.93M | 23.39M | 7.00M | 218.71M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 113.43M | 157.81M | 333.98M | 378.02M |
| Operating Income | -14.44M | -36.42M | -44.27M | -35.34M | - | -62.50M | -134.43M | -326.98M | -159.31M |
| EBITDA | - | - | - | - | - | -58.99M | -130.42M | -323.14M | -154.72M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | -58.66M | -112.96M | -274.48M | -113.70M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -11.86M | -34.35M | -41.98M | -34.49M | - | -58.66M | -112.96M | -274.48M | -113.70M |
| Diluted EPS | - | - | - | -1.40 | - | -1.42 | -1.96 | -3.36 | -1.28 |
| R&D Expense | 12.38M | 31.75M | 34.32M | 39.70M | 58.16M | 89.54M | 129.51M | 294.67M | 314.70M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 96.54M | 113.00M | 298.27M | 381.35M | 387.97M | 649.32M | 1.12B | 1.11B |
| Total Equity | -4.13M | -15.74M | -48.95M | 100.40M | 198.27M | 301.51M | 349.45M | 621.09M | 1.06B | 1.02B |
| Cash & Equivalents | - | 5.96M | 20.50M | 34.07M | 72.04M | 92.05M | 68.63M | 157.02M | 84.38M | 112.83M |
| Total Liabilities | - | - | 7.10M | 12.60M | 100.00M | 79.83M | 38.51M | 28.23M | 64.94M | 86.39M |
| Current Liabilities | - | - | 5.41M | 6.94M | 38.64M | 45.16M | 31.72M | 27.10M | 46.07M | 58.81M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.22M | -27.62M | -39.31M | 55.46M | -55.78M | -87.17M | -115.22M | -247.58M | -71.10M |
| Investing Cash Flow | -8.93M | -63.18M | 2.27M | -146.24M | -69.67M | -33.40M | -158.46M | -502.56M | 69.98M |
| Financing Cash Flow | 17.49M | 105.38M | 50.61M | 128.75M | 145.45M | 97.17M | 362.72M | 677.55M | 29.78M |
| Capital Expenditure | -1.76M | -1.71M | -1.35M | -493.00K | -2.64M | -3.44M | -2.37M | -3.86M | -2.37M |
| Free Cash Flow | -13.98M | -29.33M | -40.67M | 54.97M | -58.42M | -90.62M | -117.59M | -251.44M | -73.47M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -180.9% | - | -122.7% | -574.9% | -4,671.1% | -72.8% |
| Net Margin % | - | - | - | -176.6% | - | -115.2% | -483.0% | -3,921.1% | -52.0% |
| ROE % | 75.4% | 70.2% | -41.8% | -17.4% | - | -16.8% | -18.2% | -25.9% | -11.1% |
| ROCE % | - | -40.0% | -41.7% | -13.6% | - | -17.5% | -21.6% | -30.3% | -15.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 16.06% | 14.11M | $565.93M |
| 2 | Blackrock Inc. | 10.12% | 8.89M | $356.71M |
| 3 | Jupiter Topco LLC | 9.77% | 8.58M | $344.14M |
| 4 | Capital Research Global Investors | 6.08% | 5.34M | $214.38M |
| 5 | Baker Bros. Advisors, LP | 5.70% | 5.01M | $200.95M |
| 6 | State Street Corporation | 5.18% | 4.55M | $182.46M |
| 7 | Vanguard Capital Management LLC | 4.70% | 4.13M | $165.76M |
| 8 | Logos Global Management LP | 3.41% | 3.00M | $120.33M |
| 9 | Adage Capital Partners GP L.L.C. | 3.09% | 2.72M | $108.91M |
| 10 | Deerfield Management Company, L.P | 3.09% | 2.71M | $108.88M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for IDYA
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxONFZKZG5hRFNHSWM0M1E0YjJ1R0hrUXVIUFVLU1NPLU1sT29tdkZvVDVGdmZjak51b0RYc1hITW56RjdWcEhQYi1nbU9sbU52bXdQWDNOQnc3RkxFRXNHbkZLNkNzODEwNWNQTm4ycmY3QlF6allmMkJNdnNIRFczdU5WTWZrTzBDSTRpam…
IDEAYA Biosciences Sets London R&D Day for Nov. 16 | IDYA Stock News - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxOM3JRWnp6dU1ZanNueG5sanA2LUpXdVdmTzR6bFF5N2hSM0pzbXVBNkltWks5ZmZKTEVMYi1keHpwN0N2cThOT2duZF9sZWUyV2c5dXdUM1M1cm42WmlmWmFqREZMMDRMV293VVh2aHdOWDk1Mno1WWJHWVdZbHlMU3hFTG9TZWZVcmdhSH…
IDEAYA Biosciences (IDYA) Is Up 5.2% After Genentech KRAS G12D Trial Collaboration News - Has The Bull Case Changed? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxOT1BjOVZLakhtaWF2WHF3NlVlT1U3TFZYSW42TE9zQXZ6QlZSckZDSVBhanZ6RTVxajVXUmZuY252Z1JuT1lnRl9Cc1hYaVhIU051bWFBLUhxN0U2VFhULU5SVFZadGtwMTZRZ0h0dl9RNmNiMF9OU3RUb3JiX25wdVBxXzgzbXd1RnBWNF…
Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxQdEhSYV9uUndPVmx1UVVaZ2k2b3ZrU28xemhMMXVyRDZZWlZ0U0IteGFEUElEazE0NXJPVDVJZlBHc01EdjZRS09zVjFXWnd3eGpGZk90ZXhGN2E3R0Jub01mSUtjT1N4cG00eUthYWtCYU1UMGRWVW9vLW56YnM4VW9Va2d2ZVNwZi1mdk…
IDYA Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9oNWszRm5oZDZ2aUE5TjVCNEMydHRXM2p6MkZ2TTFTejBfUjVRUDM3d2x4NzZ6aDJtVUhsREdxcElUN25kNXh2dnpKSVZKT3VGbVBOTFBJenA1T0tVX0dwQllod2tSb0M5UXB2X2wxRWFoU0FZLUkzcWxR?oc=5" target="_blank">IDY…
IDYA - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE56NzMzY3M4MDlyWWNRTEU5QmU1SFhLM3BsNHdlXzZHZGV2Tkozb2FwOG9SaE1pY1pPbmNPNklkNzM0c0RnNlE?oc=5" target="_blank">IDYA</a> <font color="#6f6f6f">Finviz</font>…
IDYA — Frequently Asked Questions
What is the current share price of IDEAYA Biosciences, Inc. (IDYA)?
As of 2026-09-07 16:24 PDT, IDEAYA Biosciences, Inc. (IDYA) trades at $39.86 on NasdaqGS. Its 52-week range is $23.39 to $42.48.
What is the market capitalisation of IDYA?
IDEAYA Biosciences, Inc. (IDYA) has a market capitalisation of $3.84B on NasdaqGS.
What is the P/E ratio of IDYA?
IDYA trades at a trailing price-to-earnings (P/E) ratio of -20.76. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 3.47.
What is the return on equity (ROE) of IDYA?
IDYA has a return on equity (ROE) of -16.22%. Its return on capital employed (ROCE) is -15.17%.
Is IDYA a good stock to buy?
This page provides a data-driven analysis of IDEAYA Biosciences, Inc. (IDYA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.